Metabolic Disease Program Clinical Studies

1 - 2 of 2

Natural History of Homocystinuria

The goal of this study is to observe patients with Homocystinuria (CBSDH) over 3 years to learn how their disease is managed under regular circumstances. This study does not involve any investigational medications, but will provide information to researchers who are currently developing a medication to treat the disease. The study has 5 main parts, all of which are provided free of charge to participants: DXA exam, blood draws, ophthalmology exam, cognitive testing, and physical exams. To learn more about the study, please contact our team via the information listed below.

RGX-111 Gene Therapy in Patients With Mucopolysaccharidosis Type I (MPS I)

This study will evaluate the safety and tolerability of RGX-111 in patients with Mucopolysaccharidosis Type I with a neurocognitive deficit that are at least 4 months old. This study involves administration of the RGX-111, general anesthesia, lumbar puncture, blood draws, MRI, ultrasound, electrocardiogram, echocardiogram, hearing test, and chart review. If you have questions or would like to learn more about the study, please contact the Principal Investigator, Dr. Ficicioglu at (215) 590-3376.